Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology

GLIA

Volumn 29, Issue 4, 2000, Pages 366-375

  Bitsch, Andreas ^a   Kuhlmann, Tanja ^b   Da Costa, Christiane ^a   Bunkowski, Stephanie ^a   Polak, Thomas ^a   Brück, Wolfgang ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Inst fur Neuropathologie Char   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Demyelination; Macrophages; Microglia; T lymphocytes

Indexed keywords

ANIMAL MODEL; DEMYELINATION; DISEASE MODEL; DNA FRAGMENT; IN SITU HYBRIDIZATION; MACROPHAGE; MESSENGER RNA; MULTIPLE SCLEROSIS; MYELIN DEGRADATION PRODUCT; OLIGODENDROGLIA; REMYELINIZATION; T LYMPHOCYTE; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; APOPTOSIS; BIOPSY, NEEDLE; DEMYELINATING DISEASES; DNA FRAGMENTATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034652558     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y     Document Type: Article

References (55)

1. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, Matthieu JM, Gardinier MV, Dornmair K, Linington C. 1995. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 63:17-27.
2. Altschul SF, Madde, TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-402.
3. Aranguez I, Torres C, Rubio N. 1995. The receptor for tumor necrosis factor on murine astrocytes: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus. Glia 13:185-194.
4. Aukrust P, Froland SS, Liabakk NB, Müller F, Nordoy I, Haug C, Espevik T. 1994. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136-2143.
5. Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H. 1999. Impairment of TNF-receptor-1 signaling but not Fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 154:1417-1422.
6. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin, J. 1988. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318-323.
7. Bitsch A, da Costa C, Bunkowski S, Weber F, Rieckmann P, Brück W. 1998. Identification of macrophage populations expressing tumor necrosis factor alpha mRNA in acute multiple sclerosis. Acta Neuropathol 95:373-377.
8. Bitsch A, Wegener C, da Costa C, Bunkowski S, Reimers CD, Prange HW, Brück W. 1999. Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler 5:138-146.
9. Bonetti B, Raine CS. 1997. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 42:74-84.
10. Breitschopf H, Suchanek G, Gould RM, Coleman DR, Lassmann H. 1992. In situ hybridisation with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol 84:581-587.
11. Brosnan CF, Cannella B, Battistini L, Raine CS. 1995. Cytokine localisation in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45: S16-S21.
12. Brosnan CF, Litwak MS, Schroeder CE, Selmaj K, Raine CS, Arezzo JC. 1989. Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit. J Neuroimmunol 25:227-239.
13. Brück W, Schmied M, Suchanek G, Brück Y, Breitschopf H, Poser S, Piddlesden S, Lassmann H. 1994. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 35:65-73.
14. Brück W, Sommermeier N, Bergmann M, Zettl U, Goebel HH, Kretzschmar HA, Lassmann H. 1996a. Macrophages in multiple sclerosis. Immunobiology 195:588-600.
15. Brück Y, Brück W, Kretzschmar HA, Lassmann H. 1996b. Evidence for neuronal apoptosis in pontosubicular neuron necrosis. Neuropathol Appl Neurobiol 22:23-29.
16. Cannella B, Raine CS. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435.
17. Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, Fontana A. 1999. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 29:626-632.
18. Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fontana A. 1997. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 185:2177-2182.
19. Gold R, Hartung HP, Lassmann H. 1997. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 20:399-404.
20. Hisahara S, Shoji S, Okano H, Miura M. 1997. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 69:10-20.
21. Hofman FM, Hinton DR, Johnson K, Merrill JE. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607-612.
22. Hohlfeld R. 1997. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865-916.
23. Kuroda Y, Shimamoto Y. 1991. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 34:159-164.
24. Lassmann H, Raine CS, Antel J, Prineas JW. 1998. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86:213-217.
25. Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465.
26. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC. 1998. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4: 78-83.
27. Logel J, Dill D, Leonard S. 1992. Synthesis of cRNA probes from PCR-generated DNA. Biotechniques 13:604-610.
28. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6:259-274.
29. Lucchinetti CF, Rodriguez M. 1997. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc 72:665-678.
30. Lumsden CE. 1970. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: North-Holland Publishing Company, p 217-309.
31. Martin D, Near SL, Bendele A, Russell DA. 1995. Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein. Exp Neurol 131:221-228.
32. Martin R, McFarland HF, McFarlin DE. 1992. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153-187.
33. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
34. Myers LW, Ellison GW, Merrill JE, El Hajjar A, St. Pierre B, Hijazin M, Leake BD, Bentson JR, Nuwer MR, Tourtellotte WW, Davis P, Granger D, Fahey JL. 1998. Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase. Neurology 51:1483-1486.
35. Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW. 1985. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 13:6361-6373.
36. Nguyen PCB, McCombe PA, Pender MP. 1997. Increased apoptosis of T-lymphocytes and macrophages in the central nervous and peripheral nervous system of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. J Neuropathol Exp Neurol 56:58-69.
37. Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, Lassmann H. 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311-1322.
38. Paya CV, Leibson PJ, Patick AK, Rodriguez M. 1990. Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha. Int Immunol 2:909-913.
39. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
40. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S. 1995. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82-88.
41. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172:1193-1200.
42. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G, Wekerle H, Lassmann H. 1993. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol 143:446-452.
43. Selmaj K, Papierz W, Glabinski A, Kohno T. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I J Neuroimmunol 56:135-141.
44. Selmaj K, Raine CS, Cannella B, Brosnan CF. 1991a. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954.
45. Selmaj K, Raine CS, Cross AH. 1991b. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30:694-700.
46. Selmaj KW, Raine CS. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339-346.
47. Selmaj KW, Raine CS. 1995. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45:S44-S49.
48. Sriram S, Rodriguez M. 1997. Indictment of the microglia as the villain in multiple sclerosis. Neurology 48:464-470.
49. Stangel M, Schumacher HC, Ruprecht K, Boegner F, Marx P. 1997. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol. Invest 26:569-578.
50. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bö, L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
51. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody CA2. Neurology 47:1531-1534.
52. Waxman SG. 1988. Clinical course and electrophysiology of multiple sclerosis. Adv Neurol 47:157-184.
53. Woodroofe MN, Cuzner ML. 1993. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5:583-588.
54. Wride MA, Sanders EJ. 1995. Potential roles for tumour necrosis factor alpha during embryonic development. Anat Embryol 191: 1-10.
55. Zhao B, Schwartz JP. 1998. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res 52:7-16.